Integrating Plasma High-Sensitivity C-Reactive Protein and Myeloperoxidase for Risk Prediction in Chronic Systolic Heart Failure

Congestive Heart Failure

Volumn 17, Issue 3, 2011, Pages 105-109

  Wilson Tang, W H ^a   Shrestha, Kevin ^a   Troughton, Richard W ^b   Borowski, Allen G ^a   Klein, Allan L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; MYELOPEROXIDASE;

ADULT; ARTICLE; CHRONIC DISEASE; ECHOCARDIOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SYSTOLIC HEART FAILURE;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHRONIC DISEASE; COHORT STUDIES; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEROXIDASE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 79957454382     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2011.00221.x     Document Type: Article

References (13)

1. Petersen JW, Felker GM. Inflammatory biomarkers in heart failure. Congest Heart Fail. 2006;12:324-328.
2. Felker GM, Cotter G. Unraveling the pathophysiology of acute heart failure: an inflammatory proposal. Am Heart J. 2006;151:765-767.
3. Tang WH, Shrestha K, Van Lente F, et al. Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am J Cardiol. 2008;101:370-373.
4. Tang WH, Tong W, Troughton RW, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol. 2007;49:2364-2370.
5. Troughton RW, Prior DL, Pereira JJ, et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol. 2004;43:416-422.
6. Wood P. The erythrocyte sedimentation rate in diseases of the heart. Q J Med. 1936;5:1-19.
7. Nahrendorf M, Sosnovik D, Chen JW, et al. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation. 2008;117:1153-1160.
8. Rudolph V, Andrie RP, Rudolph TK, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med. 2010;16:470-474.
9. Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation. 2007;116:249-257.
10. Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation. 2007;116:1242-1249.
11. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-2261.
12. Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007;50:607-613.
13. Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1054-1060.